Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Illinois Wellness Insider.
Press releases published on May 7, 2025
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 7, 2025
Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPP Plan to initiate Phase 2 study of DISC-3405 in …
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
GlobeNewswire
·
May 7, 2025
The availability of neffy 1 mg extends protection to younger, school-aged children—who make up nearly 23% of people needing epinephrine Visit neffy.com for savings and support programs and pay as little as $25 (if eligible) in preparation for summer travel …
Erasca to Present at the Bank of America Securities Health Care Conference
GlobeNewswire
·
May 7, 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today …
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)
GlobeNewswire
·
May 7, 2025
CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver …
Jack.org Appoints New President and Chief Executive Officer
GlobeNewswire
·
May 7, 2025
Photo Caption: Michael Braithwaite joins Jack.org as President and CEO on June 16 TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- Jack.org is thrilled to announce the appointment of Michael Braithwaite (he/him) as its new President and Chief Executive Officer ( …
Jack.org nomme un nouveau président et directeur général
GlobeNewswire
·
May 7, 2025
Légende de la photo : Michael Braithwaite deviendra le nouveau PDG de Jack.org le 16 juin. TORONTO, 07 mai 2025 (GLOBE NEWSWIRE) -- Jack.org est ravi d’annoncer la nomination de Michael Braithwaite (il/lui) au poste de nouveau président et directeur …
Respect Together Honors 50 Years of Impact and Charts a New Era for Survivors
GlobeNewswire
·
May 7, 2025
Hershey, Pennsylvania, May 07, 2025 (GLOBE NEWSWIRE) -- Respect Together commemorated its 50th Anniversary on Wednesday evening with a powerful event at the Hershey Country Club, bringing together survivors, advocates, community leaders, and public …
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
GlobeNewswire
·
May 7, 2025
Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial Enrolling Globally BRISBANE, Calif., May 07, 2025 (GLOBE …
NewGenIVF Introduces NewGenSort to Support Men’s Reproductive Health Across Asia
GlobeNewswire
·
May 7, 2025
BANGKOK, May 07, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced an …
Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results
GlobeNewswire
·
May 7, 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical …
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
GlobeNewswire
·
May 7, 2025
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 07, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. ( …
Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
GlobeNewswire
·
May 7, 2025
Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025; Initiation of VTP-1000 multiple ascending dose expected in the second half of …
ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update
GlobeNewswire
·
May 7, 2025
WESTON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical-stage biopharmaceutical company specializing in first-in-class therapies for inflammatory and renal diseases, announces significant developments for …
Arialief Complaints Explained: 2025 Customer Reviews Analyzed & Verified
GlobeNewswire
·
May 7, 2025
MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- In 2025, nerve pain remains one of the most widespread yet under-discussed health challenges. Clinically known as peripheral neuropathy, this condition affects millions worldwide and manifests in various forms, …
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update
GlobeNewswire
·
May 7, 2025
- End-of-Phase 2 meeting with FDA requested for Alzheimer’s disease - - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC - - Two posters at ARVO describe zervimesine's role supporting retinal cell health - PURCHASE, N.Y., …
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
GlobeNewswire
·
May 7, 2025
PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will …
Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico
GlobeNewswire
·
May 7, 2025
MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that has assumed full commercial activities and is relaunching ONICIT® IV (palonosetron) in …
Thérapeutique Knight annonce la relance de ONICIT® au Brésil et au Mexique
GlobeNewswire
·
May 7, 2025
MONTRÉAL, 07 mai 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd'hui la prise en charge complète des activités commerciales et la relance de …
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
GlobeNewswire
·
May 7, 2025
EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at …
Repligen Corporation to Present at Upcoming May Investor Conferences
GlobeNewswire
·
May 7, 2025
WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC …